Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633471 | 1.00 | NR1H2 (0.49) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL7926868 | 1.00 | NR1H2 (0.49) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL23325142 | 0.91 | MEN1 (0.54) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL2070126 | 0.91 | MEN1 (0.54) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL20268177 | 0.91 | MEN1 (0.54) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL735207 | 0.90 | HPGD (0.54) | NR1H2HPGDKDM4EPKMMAPT | |
| SCHEMBL28278067 | 0.89 | NR1H2 (0.50) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL7260840 | 0.88 | NR1H2 (0.47) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL32687619 | 0.88 | NR1H2 (0.47) | NR1H2HPGDKDM4EPKMMEN1 | |
| SCHEMBL343699 | 0.88 | NR1H2 (0.47) | NR1H2HPGDKDM4EPKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743465-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4587424-A1 | YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS | Bridgene Biosciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-119894866-A | YAP/TAZ-TEAD oncoprotein inhibitors | 布里奇恩生物科学公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025012195-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-16 | — | — | WO | disclosed |
| CN-118955490-A | O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors | 渤健马萨诸塞州股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-112218863-B | O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors | 比奥根MA公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2024059317-A1 | YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS | BRIDGENE BIOSCIENCES, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| EP-4186899-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230117898-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2023-04-20 | — | — | US | disclosed |
| US-20150218151-A1 | NOVEL PHENYLACETAMIDE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2015-08-06 | — | — | US | disclosed |
| EP-2902390-A1 | NOVEL PHENYLACETAMIDE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | Kowa Company, Ltd. (JP) | 2015-08-05 | — | — | EP | disclosed |
| WO-2014071369-A1 | TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY | ZAFGEN, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| WO-2012169649-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-12-13 | — | — | WO | disclosed |
| EP-2245028-B1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117898-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | MGAT3, ST3GAL3, ST6GAL1 | NR1H2 3308/4885HPGD 1223/4885KDM4E 4089/4885 |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | MLLT1, BMI1, MEN1 | NR1H2 3177/4885HPGD 1971/4885KDM4E 176/4885 |
| US-20150218151-A1 | NOVEL PHENYLACETAMIDE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | GCK, GCKR, PCK1 | NR1H2 1894/4885HPGD 2502/4885KDM4E 2648/4885 |
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | HTR4, HTR3B, HTR3A | NR1H2 1480/4885HPGD 875/4885KDM4E 2230/4885 |
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | CNKSR1, KCNH1, CBR3 | NR1H2 62/4885HPGD 1910/4885KDM4E 646/4885 |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | DNPEP, CES2, AADAC | NR1H2 667/4885HPGD 1164/4885KDM4E 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.